

Media Release: Sydney, Australia. 27 February, 2019.

PHEBRA EXPANDS LANE COVE WEST HEAD OFFICE

Leading Australian pharmaceutical firm Phebra has announced a \$4million expansion of its Sydney multi-purpose sterile injectables site.

The footprint of the current Phebra facility will increase by over 3,000m² with the company taking-over the remainder of its building in Lane Cove West following the expiration of the tenant's lease.

When Phebra purchased the building in 2010 one of the advantages it envisaged was the potential for future expansion which has now been realised.

Phebra Chief Executive Officer, Dr Mal Eutick, said the expansion would boost the company's current space, warehousing, packaging and support services for its pipeline of critical medicines.

"The ability to be able to expand on the same site and in the same building is a great advantage to the Company," Dr Eutick said.

"It will significantly increase Phebra's existing capacity and allow for the expansion of our product portfolio, to meet the growth in our local and particularly export markets."

Dr Eutick said works at the expanded facility are expected to be completed by June 2019.

About Phebra

Phebra is an Australian based specialty pharmaceutical company which develops, manufactures and markets critical medicines in Australia and across the world.

At Phebra, we create critical medicines that save and improve lives.

Phebra media contact: Richard Lenarduzzi. +61 411 254 390